Product nameAnti-Fibrinogen alpha chain antibody [EPR2919]
See all Fibrinogen alpha chain primary antibodies
DescriptionRabbit monoclonal [EPR2919] to Fibrinogen alpha chain
SpecificityThe immunogen is derived from isoform alpha-E, UniProt accession P02671-1, and the antibody is not expected to detect isoform alpha.
Tested applicationsSuitable for: WB, IP, IHC-P, ICC/IFmore details
Species reactivityReacts with: Rat, Human
within Human Fibrinogen alpha chain aa 750-850. The exact sequence is proprietary. The immunogen is derived from isoform alpha-E, UniProt accession P02671-1, and the antibody is not expected to detect isoform alpha.
Database link: P02671-1
- Human hepatocellular carcinoma tissue Human plasma, fetal liver and HepG2 whole cell lysate (ab7900)
Mouse: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab92572 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 95 kDa.|
|IHC-P||1/50 - 1/100.
Antigen retrieval plus the use of an HRP/AP polymerized secondary antibody is highly recommended for enhanced staining.
FunctionFibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
Involvement in diseaseDefects in FGA are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
Defects in FGA are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
Sequence similaritiesContains 1 fibrinogen C-terminal domain.
DomainA long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
modificationsThe alpha chain is not glycosylated.
Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Phosphorylation sites are present in the extracelllular medium.
- Information by UniProt
- Ac1873 antibody
- Fba5e antibody
- FGA antibody
Rat platelet lysate at 20 µg
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 95 kDa
Observed band size: 110 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutes
Blocking and diluting buffer: 5% NFDM/TBST.
Immunocytochemistry/ Immunofluorescence analysis of HepG2 (human hepatocellular carcinoma epithelial cell) labeling Fibrinogen alpha chain with ab92572 at a dilution of 1/250. Confocal image showing cytoplasmic staining in HepG2 cells. ab150077 AlexaFluor®488 Goat anti-Rabbit at 1/1000 dilution was used a secondary antibody. Cells were fixed with 4% Paraformaldehyde and permeabilised with 0.1% TritonX-100. ab195889, Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 was used as counterstain and nuclei were stained with DAPI (blue).
ab92572 at a dilution of 1/100 immunoprecipitating Fibrinogen alpha chain in human plasma.
Lane 1 (input): Human plasma (10 µg)
Lane 2 (+): ab92572 + human plasma.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab92572 in human plasma.
For western blotting, ab92572 was used as the primary antibody at a 1/1000 dilution and ab131366 VeriBlot for IP (HRP) was used as the secondary antibody (1/5000).
Blocking and dilution buffer: 5% NFDM/TBST.
Immunohistochemical analysis of paraffin-embedded human hepatocellular carcinoma using ab92572 at 1/2000 dilution.
All lanes : Anti-Fibrinogen alpha chain antibody [EPR2919] (ab92572) at 1/2000 dilution
Lane 1 : Human plasma lysate
Lane 2 : Human fetal liver lysate
Lane 3 : HepG2 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 95 kDa
This product has been referenced in:
- Cheng P et al. Prevascularization promotes endogenous cell-mediated angiogenesis by upregulating the expression of fibrinogen and connective tissue growth factor in tissue-engineered bone grafts. Stem Cell Res Ther 9:176 (2018). Read more (PubMed: 29973254) »
- Rancourt RC et al. Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalation. Am J Respir Cell Mol Biol 51:559-67 (2014). Read more (PubMed: 24796565) »